Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimerā€™s disease.

Articles by Lindsey Shapiro

GoodRx Offers MS Patients Digital Vumerity Enrollment Form

GoodRx, in collaboration with Biogen, has made the enrollment form for starting a multiple sclerosis (MS) patient on Vumerity (diroximel fumarate) available on its new “Provider Mode” digital platform. By adding the electronic enrollment form, the company hopes doctors will be able to prescribe their patients Vumerity more…

Second SPMS Patient Given Foralumab Continues to Improve

Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program. Findings from this patient have been generally consistent with those seen in the first non-active SPMS…

Understanding MS Burden, Support Needs Can Challenge Couples

Differences are evident in the perceived frequency of expressions of support needs and disease burden between people withĀ  multiple sclerosis (MS) and their life partners, a Swiss study found. People without MS responded in a survey to feeling their partnersā€™ communication about these issues was more frequent than the…

Progression Without Relapse Also Common in RRMS, Patients Say

Nearly two-thirds of people with relapsing-remitting multiple sclerosis (RRMS) report disease progression independent of relapses, according to a survey involving more than 4,500 multiple sclerosisĀ (MS) patients in Germany. This finding supports evidence pointing to progression independent of relapse activity (PIRA) as an underestimated contributing factor in RRMS.

Guidelines for Approval of DMT Biosimilars, Use In Europe Drafted

Biosimilar, or ā€œfollow-on,ā€ forms of disease-modifying therapies (DMTs) that have been approved in a highly regulated area can be considered as safe and effective as their reference medications, according to multiple sclerosis (MS) experts. A biosimilar is a medication that’s highly similar to an existing biological medication in…

Exergaming May Be Better Than Other Exercises, But Study Needed

Virtual reality exergames ā€” immersive video games whose play involves physical exercise ā€” may be better than conventional exercise at easing certain symptoms of multiple sclerosis (MS), such as balance and upper limb function, a review of published studies suggested. However, differences among the evaluated studies ā€” in matters…

PAS002 Vaccine Shows Efficacy in MS Mouse Model

Pasithea Therapeutics investigational multiple sclerosis vaccine, PAS002, effectively delayed disease onset and reduced disease severity in a mouse model of the neurodegenerative condition, according to data from a preclinical study. The vaccine, which is designed to promote immune tolerance to a specific myelin protein, also reduced the severity…